Editas Medicine received approval in October 2026 to initiate the Strive trial of EDIT-401 in Australia, with dosing on track for 2026. Net loss was $66.6 million for the nine months ended September 30, 2026, versus $154.4 million in 2025.
EDIT · Editas Medicine, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $1.71
- Open
- $1.80
- Day range
- $1.70–1.83
- 52-week closing range
- $1.67–3.75
- Average volume, 30 days
- 2.2M
- Short interest
- 38.7M · 25.1% of shares · 17.6 days
- Short volume, last session
- 65%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Editas Medicine received HREC approval and completed TGA notification for the Phase 1/2 Strive study of EDIT-401 in Australia, with dosing planned this year. Cash and marketable securities totaled $190.2 million, supporting a runway into the second half of 2028.
Editas Medicine, Inc. received approval to initiate the Phase 1/2 Strive™ trial of EDIT-401 in Australia; New Zealand review is pending, and initial safety and tolerability data are expected in the first quarter of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EDIT
this stock
Editas Medicine, Inc.
|
$263.92M | -16.6% | +132.6% | — | 25.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 22
Editas Medicine received HREC approval and completed TGA notification for the Phase 1/2 Strive study of EDIT-401 in Australia, with dosing planned this year. Cash and marketable securities totaled $190.2 million, supporting a runway into the second half of 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EDIT | -20.1% | -31.3% | -48.8% | -36.0% | -16.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -14.6% | -25.0% | -43.2% | -30.7% | -21.6% |